Loading
Life sciences · Journal article
Journal of Orthopaedic Experience & Innovation · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated benefits in diabetes and obesity management, but their impact on outcomes following unicompartmental knee arthroplasty (UKA) remains unexplored. This study evaluates the influence of preoperative GLP-1 agonist use on postoperative complications following UKA. Methods A national claims database was queried to identify patients undergoing primary UKA between 2010 and 2021. Patients with preoperative GLP-1 prescriptions were 1:1 propensity-matched to non-users based on age, sex, Charlson Comorbidity Index, diabetes, obesity, and tobacco use, yielding two balanced cohorts of 1,138 patients each (mean age 61.1 years, 53% female). Successful matching was confirmed with standardized mean differences <0.001 for all variables. Primary outcomes included 90-day and 2-year complications. Categorical variables were compared using chi-square tests with relative risk reduction (RRR) and 95% confidence intervals. Results At 90 days, GLP-1 users demonstrated significantly lower rates of deep vein thrombosis (0.4% vs. 1.4%; RRR = 75%; 95% CI: 15-93%; P = 0.013), wound complications (0.0% vs. 1.2%; RRR = 100%; P < 0.001), and surgical site infections (0.1% vs. 1.2%; RRR = 93%; 95% CI: 34-99%; P = 0.002) compared to non-users. No significant differences were observed in pulmonary embolism, acute kidney injury, urinary tract infection, hematoma, transfusion requirements, or readmissions. At 2 years, GLP-1 users had significantly lower rates of prosthetic joint infection (0.4% vs. 1.4%; RRR = 75%; 95% CI: 15-93%; P = 0.013). All-cause revision rates showed a favorable trend in GLP-1 users but did not reach statistical significance (2.3% vs. 3.6%; RRR = 37%; P = 0.083). Conclusion Preoperative GLP-1 receptor agonist use was associated with lower rates of thromboembolic, infectious, and wound-related complications following UKA without an observed increase in other adverse events. These findings may reflect both medication-related effects and broader improvements in metabolic optimization. Prospective studies with detailed metabolic data are needed to further evaluate these associations.